Alesta Therapeutics, a Leiden, the Netherlands-based biotechnology company focused on developing transformative small molecule therapies for rare diseases, raised €65M in Series A funding.
The round was led by Frazier Life Sciences and Droia Ventures, with participation from Novartis Venture Fund, RTW Investments, RV Invest, Thuja Capital and SSI Strategy.
The company intends to use the funds to expand operations and its R&D sector.
Alesta Therapeutics is biotechnology company committed to developing novel oral small molecule therapies for underserved rare diseases. Its lead asset, ALE1, is being developed for hypophosphatasia (HPP), a rare genetic disorder with significant unmet needs. Alesta is also advancing ALE2, a candidate to treat Charcot-Marie-Tooth (CMT) disease.
Alesta is led by:
- Ilan Ganot, Chief Executive Officer
- Matthias Van Woensel, Ph.D., Chief Scientific Officer
- Benit Maru, MBChB, Ph.D., Chief Medical Officer
In addition to the CEO, Alesta’s Board of Directors includes:
- Laura Brass, Ph.D., Novartis Venture Fund
- Luc Dochez, Droia Ventures
- Dan Estes, Ph.D., Frazier Life Sciences
- Janwillem Naesens, Droia Ventures
FinSMEs
08/01/2025